SEMA4D has the capacity of inducing B-cells to aggregate and improves their viability (33),and high expression levels of SEMA4D are significantly correlated with poor prognosis for a number of cancers including colon (34), ovarian epithelial (35) and cervical (36) as well as soft tissue sarcoma (37). Here, SEMA4D is linked to soft tissue sarcoma.